Trajenta 5 mg Tablet

Trajenta 5 mg Tablet is an anti-diabetic medicine with active ingredient Linagliptin (5mg). It is prescribed to treat type 2 diabetes mellitus in adults. It works by controlling blood sugar levels in people with diabetes.

This medicine functions by minimizing blood sugar by stimulating the pancreas to secrete more insulin. It can be taken with or without food but at the same time each day to get effective results. Don't take more than the recommended dose.​

• Type 2 diabetes mellitus

Trajenta 5 mg Tablet may cause some side effects that vary from one patient to another. Most side effects do not require any medical attention and disappear as your body adjusts to the medicine.

Common side effects include:

• Cough
• Hypoglycemia (low blood glucose level)
• Nasopharyngitis (inflammation of the throat and nasal passages)
• Constipation
• Vomiting
• Diarrhea

Seek medical attention in case of any unusual or severe side effects immediately.

• Take Trajenta 5 mg Tablet in dosage as prescribed by the doctor. Dosage and the duration determined as per the patients health condition.
• This tablet should be swallowed as a whole with water. Don't crush, chew, or break the tablet. It should be taken with food. Never skip a dose or double dose.​​
  

Trajenta 5 mg Tablet is an anti-diabetic medicine with active ingredient Linagliptin (5mg). Linagliptin is known as a DPP-4 inhibitor that minimizes blood sugar by stimulating the pancreas to secrete more insulin. It lowers fasting as well as post-meal sugar levels.​

• Chandrasekaran, S., Kalaivani, K., & Thamizhanban, D. Bioequivalence Assessment of the Fixed Dose Combination of Linagliptin/Metformin (2.5 mg/850mg) Film Coated Tablets in Healthy Human Subjects: A Randomized, Open-Label, Two-Period Crossover Study. https://www.texilajournal.com/medicine/article/3380-bioequivalence-assessment-of
• Chatterjee, S., & Jat, R. K. (2021). Formulation and evaluation of immediate release tablet dosage form of linagliptin and metformin hydrochloride. Journal of Drug Delivery & Therapeutics, 11. https://jddtonline.info/index.php/jddt/article/view/4831
• Bhargava, A. (2015). Linagliptin/metformin HCl (fixed combination therapy) for the treatment of Type 2 diabetes mellitus. Expert Review of Endocrinology & Metabolism, 10(4), 353-363. https://pubmed.ncbi.nlm.nih.gov/30293498/
• Ross, S. A., Rafeiro, E., Meinicke, T., Toorawa, R., Weber-Born, S., & Woerle, H. J. (2012). Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Current medical research and opinion, 28(9), 1465-1474. https://pubmed.ncbi.nlm.nih.gov/22816729/
• Haak, T. (2015). Combination of linagliptin and metformin for the treatment of patients with type 2 diabetes. Clinical Medicine Insights: Endocrinology and Diabetes, 8, CMED-S10360.Chandrasekaran, S., Kalaivani, K., & Thamizhanban, D. Bioequivalence Assessment of the Fixed Dose Combination of Linagliptin/Metformin (2.5 mg/850mg) Film Coated Tablets in Healthy Human Subjects: A Randomized, Open-Label, Two-Period Crossover Study. https://pubmed.ncbi.nlm.nih.gov/25628514/
•  Ji, L., Zinman, B., Patel, S., Ji, J., Bailes, Z., Thiemann, S., & Seck, T. (2015). Efficacy and safety of linagliptin co-administered with low-dose metformin once daily versus high-dose metformin twice daily in treatment-naïve patients with type 2 diabetes: a double-blind randomized trial. Advances in therapy, 32(3), 201-215.